Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Octreotide acetate
Synonyms
Therapy Description

Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Octreotide acetate Sandostatin Lar Depot SMS 201-995 Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05701241 FDA approved Lanreotide acetate Octreotide acetate Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) Recruiting NLD | BEL 0
NCT03972488 Phase III Octreotide acetate lutetium Lu 177 dotatate + Octreotide acetate Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT05477576 Phase Ib/II Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) Recruiting USA | NLD | FRA | ESP | CAN | BRA | BEL 0


Additional content available in CKB BOOST